J. Corral

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Oncology, Pathology, Bronchial Neoplasm +9

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · Journal of Clinical Oncology · 2013 · 627 citations

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Luis Paz‐Ares, Filippo de Marinis, Mircea Dediu et al. · The Lancet Oncology · 2012 · 607 citations · Full text

Oncology, Cancer Management, Maintenance Therapy +5

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations

Tony Mok, Ying Cheng, Xiangdong Zhou et al. · Journal of Clinical Oncology · 2018 · 428 citations

Compared Dacomitinib, Advanced Nsclc, Cancer Epidemiology +13

Identification of proteomic signatures associated with lung cancer and COPD

María Dolores Pastor, Ana Nogal, Sonia Molina‐Pinelo et al. · Journal of Proteomics · 2013 · 155 citations

Proteomic Technology, Engineering, Medicine +8